For over 50 years, the field of cancer therapy has been dominated by the concept that the tumor must be the selected target of the chemotherapy delivered. Therefore, any drug with the ability to directly kill tumor cells in the laboratory was by definition a candidate for use as chemotherapy…
Neurotoxicity is a significant tumor-and treatment-related complication for a number of childhood cancer survivors. It is particularly relevant for children with brain tumors who require therapy specifically directed at the central nervous system. Despite its significance, relatively little is known about the etiology, diagnosis, prevention, or treatment of neurotoxicity. As…
Medulloblastoma is the most common primary malignant central nervous system tumor arising in childhood. Survival rates for children with medulloblastomas have nearly doubled and so has the recognition that many survivors are impaired and new forms of treatment are needed. Its understanding and management represents both the progress and challenges…
Children and adolescents who have undergone treatment for brain tumors may be more likely to exhibit behavior problems than their peers. There have been relatively few formal studies of this issue, and behavior problems have often not been included in studies of neuropsychological outcome following treatment. Studies which have been…
Brain stem tumors are perhaps the most dreaded cancers in pediatric oncology, owing to their historically poor prognosis, yet they remain an area of intense research. Brain stem tumors account for about 10 to 15% of childhood brain tumors. Peak incidence for these tumors occurs around age 6 to 9…
Page 2 of 3

Thanks to Our Sponsors